Table 2

Characteristics of trials that have used FENO to guide treatment in children with asthma

First author [ref.]Primary outcome(s)Mean age# yearsParticipantsAtopy as inclusion criterion?FEV1 <80% pred also used in treatment algorithm?FENO cut-off(s) used ppbWhat did the trial find? (FENO treatment compared to standard care)
Fritsch [21]FEV111.547YesYes20Higher midexpiratory flow, higher dose of ICS
Peirsman [22]Symptom-free days1199YesYes20Reduced exacerbations, increased LTRA and ICS dose
No difference in primary outcome
Petsky [23]Exacerbations1063NoNo10 for nonatopic, 12 with one PSPT, 20 for >1 PSPTReduced exacerbation, increased ICS dose
Pijnenburg [24]Cumulative ICS dose1284NoNo30Reduced FENO and bronchial hyperresponsiveness
No increase in ICS dose
Pike [25]ICS dose and exacerbation frequency1190NoNo≤15 and ≥25No differences in outcomes
Szefler [26]Days with asthma symptoms14546YesYes20, 30 and 40Reduced exacerbations, increased ICS dose
No difference in primary outcome.
Verini [27]Exacerbations, symptom score, treatment1264NoNo12Reduced exacerbations, improved symptom score, less asthma treatment
Voorend-van Bergen [28]Proportion of symptom-free days10181YesNo20 and 50Increased asthma control but not the primary outcome

PSPT: positive skin-prick test; LTRA: leukotriene receptor antagonist. #: where mean age is given for children in separate arms of trial, an approximate overall mean age is given; : not including 91 randomised to a web-based intervention.